TRACON Pharmaceuticals Initiates Phase 1/2 Clinical Trial for TRC105 Therapy

Strategic Insights -

TRACON Pharmaceuticals, a biotechnology company focused on developing targeted therapies, has announced that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer. This trial marks a significant step forward in the development of TRC105, a monoclonal antibody that targets CD105, a receptor essential for angiogenesis - the process of new blood vessel formation in tumors. TRC105 is expected to inhibit angiogenesis and attack established tumors, demonstrating potential in treating a wide range of solid cancer types. The trial will be conducted in collaboration with the National Cancer Institute and TRACON under a Cooperative Research and Development Agreement (CRADA), highlighting the commitment to advancing cancer treatment options.

Key Takeaways:

  • TRACON Pharmaceuticals has initiated a Phase 1/2 clinical trial for TRC105 therapy in patients with castrate-resistant prostate cancer, in collaboration with the National Cancer Institute.
  • TRC105 is a monoclonal antibody targeting CD105, a receptor crucial for angiogenesis, and is expected to demonstrate activity against various solid cancer types.
  • The National Cancer Institute and TRACON have entered into a 5-year Cooperative Research and Development Agreement (CRADA) to develop TRC105 as a prostate cancer treatment.
  • TRACON Pharmaceuticals specializes in licensing, developing, and commercializing targeted therapies for oncology and ophthalmology.
  • TRC105 was developed by the Seon group at Roswell Park Cancer Institute and licensed to TRACON.
  • This trial represents a significant step forward in the development of a potential treatment for prostate cancer, the most common cancer affecting men in the United States.

Statistics:

  • 5-year period for the Cooperative Research and Development Agreement (CRADA) between the National Cancer Institute and TRACON.
  • Prostate cancer is the most common cancer affecting men in the United States.
  • TRACON Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies for oncology and ophthalmology.

Sources:

  • TRACON Pharmaceuticals, Inc.
  • National Cancer Institute
  • Roswell Park Cancer Institute